Royalty Pharma plc (FRA:RPD)

Germany · Delayed Price · Currency is EUR

33.55

+0.41 (1.24%)

At close: Jan 30, 2026

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2018	FY 2016	FY 2015
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Cystic Fibrosis Franchise Revenue	819.92M	826.21M
Evrysdi Revenue	213.41M	224.43M
Trelegy Revenue	149.91M	146.92M
Tremfya Revenue	149.47M	147.14M
Tysabri Revenue	120.29M	124.82M
Imbruvica Revenue	-	131.09M
Other Products Revenue	636.85M	548.82M
Total Income from Financial Royalty Assets	2.23B	2.15B
Other Royalty Income and Revenue	119.28M	114.15M
Revenue (Other)	-213.41M	-224.43M
Revenue (Total)	2.35B	2.26B

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2018	FY 2016	FY 2015
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Portfolio Receipts	3.12B	2.80B

Updated Sep 30, 2025. Data Source: Fiscal.ai.